Amanda Howard-Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda Howard-Thompson has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Luckey
Jackson-Madison County General Hospital, 620 Skyline Drive, Jackson, TN 38301, USA
1 shared publication Anna Dutton
Regional One Health
1 shared publicationBeth A. Choby
Department of Medical Education, University of Tennessee Health Science Center, Room 1002, 910 Madison Avenue, Memphis, TN 38163, USA
1 shared publicationBob L. Lobo
MUH, and Associate Professor, College of Pharmacy, UT
1 shared publicationBryan Cartmell
College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA
1 shared publicationChrista George
Department of Clinical Pharmacy and Family Medicine, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38163, USA
1 shared publication
Latest Publications
- 25 February 2022
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 79 (15) , 1250-1254
Acute elevation of liver function test values following concomitant administration of dabigatran and primidone
Purpose: We report a unique case of transiently elevated liver function test (LFT) values associated with concurrent use of dabigatran and primidone, which has not previously been described in the scientific literature. Summary: Management of drug-drug interactions requires a fundamental understanding of pharmacodynamic and pharmacokinetic parameters. Despite the use of available best predictive models, idiosyncratic drug reactions may still occur when a newly approved medication begins to be used in the general population. We report a case of a possible interaction (Naranjo adverse drug reaction probability score of 3, Roussel Uclaf causality assessment method score of 3) between dabigatran and primidone in a 70-year-old Caucasian male resulting in a transient elevation of LFT values. The patient was transitioned from warfarin to dabigatran in the setting of persistently subtherapeutic international normalized ratio values. During a routine outpatient follow-up appointment approximately 1 month after dabigatran initiation, the patient was discovered to have LFT values greater than 5 times the upper limit of normal. Dabigatran was thus discontinued; the patient was returned to warfarin therapy and their LFT values returned to baseline. Conclusion: Studies have indicated a potential for reduced dabigatran efficacy with concurrent use of primidone due to P-glycoprotein induction, thereby potentiating the risk for thrombosis. To date, reports of this interaction resulting in hepatic injury are lacking. The present case suggests that this interaction may be clinically significant with regard to selection of antithrombotic medication therapy in patients on primidone therapy.
- 25 February 2022
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 79 (15) , 1250-1254
Acute elevation of liver function test values following concomitant administration of dabigatran and primidone
Purpose: We report a unique case of transiently elevated liver function test (LFT) values associated with concurrent use of dabigatran and primidone, which has not previously been described in the scientific literature. Summary: Management of drug-drug interactions requires a fundamental understanding of pharmacodynamic and pharmacokinetic parameters. Despite the use of available best predictive models, idiosyncratic drug reactions may still occur when a newly approved medication begins to be used in the general population. We report a case of a possible interaction (Naranjo adverse drug reaction probability score of 3, Roussel Uclaf causality assessment method score of 3) between dabigatran and primidone in a 70-year-old Caucasian male resulting in a transient elevation of LFT values. The patient was transitioned from warfarin to dabigatran in the setting of persistently subtherapeutic international normalized ratio values. During a routine outpatient follow-up appointment approximately 1 month after dabigatran initiation, the patient was discovered to have LFT values greater than 5 times the upper limit of normal. Dabigatran was thus discontinued; the patient was returned to warfarin therapy and their LFT values returned to baseline. Conclusion: Studies have indicated a potential for reduced dabigatran efficacy with concurrent use of primidone due to P-glycoprotein induction, thereby potentiating the risk for thrombosis. To date, reports of this interaction resulting in hepatic injury are lacking. The present case suggests that this interaction may be clinically significant with regard to selection of antithrombotic medication therapy in patients on primidone therapy.
- Open Access
- 23 February 2016
- Published by Sciedu Press in Case Reports in Internal Medicine
- Vol. 3 (2) , p18
Management of increased response to warfarin associated with decompensated heart failure in an outpatient family medicine clinic
We report a 55-year-old patient with left ventricular heart failure and an ejection fraction of < 10% that was placed on warfarin therapy (42 mg/week) for the presence of a left ventricular thrombus. Thirty-nine days after hospital discharge, the patient presented with complaints of increased dyspnea over the previous week and required a wheelchair for mobility. The patient’s weight had increased by 28 lbs (13 kg). As the patient’s weight increased, his dose requirements for warfarin decreased resulting in an almost 30% reduction in his warfarin dose. Two months after the initiation of metolazone therapy, the patient lost 53 lbs (24 kg) and his warfarin requirements increased eventually placing him on his original prescribed dose of 42 mg/week. This case shows that if a patient’s decompensated heart failure can be controlled with few exacerbations and close monitoring, they can be safely managed on warfarin in an outpatient setting.
- 23 February 2016
- Published by Sciedu Press in Case Reports in Internal Medicine
- Vol. 3 (2) , p18
Open AccessManagement of increased response to warfarin associated with decompensated heart failure in an outpatient family medicine clinic
We report a 55-year-old patient with left ventricular heart failure and an ejection fraction of < 10% that was placed on warfarin therapy (42 mg/week) for the presence of a left ventricular thrombus. Thirty-nine days after hospital discharge, the patient presented with complaints of increased dyspnea over the previous week and required a wheelchair for mobility. The patient’s weight had increased by 28 lbs (13 kg). As the patient’s weight increased, his dose requirements for warfarin decreased resulting in an almost 30% reduction in his warfarin dose. Two months after the initiation of metolazone therapy, the patient lost 53 lbs (24 kg) and his warfarin requirements increased eventually placing him on his original prescribed dose of 42 mg/week. This case shows that if a patient’s decompensated heart failure can be controlled with few exacerbations and close monitoring, they can be safely managed on warfarin in an outpatient setting.
- 16 October 2014
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 36 (6) , 1126-1129
Flushing and pruritus secondary to prescription fish oil ingestion in a patient with allergy to fish
- 16 October 2014
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 36 (6) , 1126-1129
Flushing and pruritus secondary to prescription fish oil ingestion in a patient with allergy to fish
- 1 August 2014
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 44 (2) , 178-179
Toxic epidermal necrolysis reaction associated with the use of moxifloxacin
- 1 August 2014
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 44 (2) , 178-179
Toxic epidermal necrolysis reaction associated with the use of moxifloxacin
- Open Access
- 4 June 2014
- Published by Wiley in Case Reports in Medicine
- Vol. 2014, 1-6
Graves’ Disease and Treatment Effects on Warfarin Anticoagulation
Background. Hyperthyroidism causes an increased hypoprothrombinemic response to warfarin anticoagulation. Previous studies have demonstrated that patients with hyperthyroidism require lower dosages of warfarin to achieve a therapeutic effect. As hyperthyroidism is treated and euthyroidism is approached, patients may require increasing warfarin dosages to maintain appropriate anticoagulation. We describe a patient’s varying response to warfarin during treatment of Graves’ disease.Case Presentation. A 48-year-old African American female presented to the emergency room with tachycardia, new onset bilateral lower extremity edema, gradual weight loss, palpable goiter, and generalized sweating over the prior 4 months. She was admitted with Graves’ disease and new onset atrial fibrillation. Primary stroke prophylaxis was started using warfarin; the patient developed a markedly supratherapeutic INR likely due to hyperthyroidism. After starting methimazole, her free thyroxine approached euthyroid levels and the INR became subtherapeutic. She remained subtherapeutic over several months despite steadily increasing dosages of warfarin. Immediately following thyroid radioablation and discontinuation of methimazole, the patient’s warfarin dose and INR stabilized.Conclusion. Clinicians should expect an increased response to warfarin in patients with hyperthyroidism and close monitoring of the INR is imperative to prevent adverse effects. As patients approach euthyroidism, insufficient anticoagulation is likely without vigilant follow-up, INR monitoring, and increasing warfarin dosages.
- 4 June 2014
- Published by Wiley in Case Reports in Medicine
- Vol. 2014, 1-6
Open AccessGraves’ Disease and Treatment Effects on Warfarin Anticoagulation
Background. Hyperthyroidism causes an increased hypoprothrombinemic response to warfarin anticoagulation. Previous studies have demonstrated that patients with hyperthyroidism require lower dosages of warfarin to achieve a therapeutic effect. As hyperthyroidism is treated and euthyroidism is approached, patients may require increasing warfarin dosages to maintain appropriate anticoagulation. We describe a patient’s varying response to warfarin during treatment of Graves’ disease.Case Presentation. A 48-year-old African American female presented to the emergency room with tachycardia, new onset bilateral lower extremity edema, gradual weight loss, palpable goiter, and generalized sweating over the prior 4 months. She was admitted with Graves’ disease and new onset atrial fibrillation. Primary stroke prophylaxis was started using warfarin; the patient developed a markedly supratherapeutic INR likely due to hyperthyroidism. After starting methimazole, her free thyroxine approached euthyroid levels and the INR became subtherapeutic. She remained subtherapeutic over several months despite steadily increasing dosages of warfarin. Immediately following thyroid radioablation and discontinuation of methimazole, the patient’s warfarin dose and INR stabilized.Conclusion. Clinicians should expect an increased response to warfarin in patients with hyperthyroidism and close monitoring of the INR is imperative to prevent adverse effects. As patients approach euthyroidism, insufficient anticoagulation is likely without vigilant follow-up, INR monitoring, and increasing warfarin dosages.
- 15 June 2008
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (12) , 1144-1147
Heparin-induced thrombocytopenia complicated by warfarin-induced skin necrosis
Purpose. A case of heparin-induced thrombocytopenia (HIT) complicated by warfarin-induced skin necrosis (WISN) is reported.
- 15 June 2008
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (12) , 1144-1147
Heparin-induced thrombocytopenia complicated by warfarin-induced skin necrosis
Purpose. A case of heparin-induced thrombocytopenia (HIT) complicated by warfarin-induced skin necrosis (WISN) is reported.